CTP-Modified Growth Hormone for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptide drugs have short circulatory half-lives due to susceptibility to denaturation and enzymatic degradation, leading to frequent injections and discomfort, and their development is hindered by unfavorable pharmacokinetics, including short serum half-life and potential toxic side effects.
Innovation Solution
Attaching chorionic gonadotrophin carboxy-terminal peptides (CTPs) to growth hormone, either singly or in tandem, to enhance stability, prolong half-life, and improve pharmacokinetic profiles, thereby reducing dosing frequency and increasing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are administered frequently to maintain therapeutic levels, then pharmacological efficacy is maintained, but patient comfort deteriorates and compliance decreases
Solution Approach 1:
The patent applies preliminary action by pre-modifying the growth hormone with PEG chains and CTP sequences before administration. This preliminary modification extends the half-life of the peptide drug, allowing therapeutic levels to be maintained for longer periods without frequent re-administration, thus improving patient comfort while preserving pharmacological efficacy
Solution Approach 2:
The patent changes the molecular parameters of the growth hormone by attaching PEG chains (molecular weight 2,000-40,000) and CTP sequences, which fundamentally alter the pharmacokinetic properties including half-life and serum stability. These parameter changes enable less frequent dosing while maintaining effective plasma concentrations
2Reliability
If peptide drugs are administered frequently to maintain therapeutic levels, then pharmacological efficacy is maintained, but dosing frequency increases leading to treatment complexity
Solution Approach 1:
The growth hormone is pre-modified with PEG and CTP to extend its half-life before administration. This preliminary action ensures that a single dose maintains therapeutic levels for an extended period, reducing the number of administrations required while preserving pharmacological efficacy
Solution Approach 2:
The patent creates a composite structure by combining growth hormone with PEG chains and CTP sequences. This composite material has improved pharmacokinetic properties including extended half-life and enhanced serum stability, allowing for reduced dosing frequency while maintaining therapeutic effectiveness
3Duration of action of stationary object
If growth hormone is modified with PEG and CTP sequences, then half-life is extended, but molecular structure complexity increases
Solution Approach 1:
The patent systematically varies PEG molecular weights (2,000-40,000) and CTP sequence configurations to optimize half-life extension. By controlling these parameters within specific ranges, the patent achieves extended duration of action while managing molecular structure complexity through defined modification patterns
4Ease of operation
If peptide drugs are designed with extended half-life to reduce dosing frequency, then patient compliance improves, but development complexity increases due to pharmacokinetic optimization requirements
Solution Approach 1:
The patent performs preliminary pharmacokinetic optimization through PEGylation and CTP attachment before clinical use. This preliminary optimization extends half-life and improves serum stability, thereby enhancing patient compliance while consolidating the complexity into the drug design phase rather than requiring complex dosing regimens
Solution Approach 2:
The patent optimizes specific parameters including PEG molecular weight (2,000-40,000) and CTP sequence configuration to achieve desired pharmacokinetic properties. By systematically adjusting these parameters, the patent balances extended half-life with manageable structural complexity, improving compliance without excessive development complexity
Data Source
AI summary
A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a growth hormone and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a growth hormone are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.